BLUE News and Press, bluebird bio Inc. From 08/09/21

Bluebird Bio, Inc. (BLUE) Q2 2021 Earnings Conference Call August 09, 2021, 08:00 AM ET Company Participants Nick Leschly – Chief Executive Officer Elizabeth Pingpank – Direct Investor Relations Andrew Obenshain – President Severe Genetic Diseases Philip Gregory – ...

Tesla (NASDAQ:TSLA) took a turn in the spotlight in midday trading on Monday. A positive analyst comment gave a boost to Elon Musk's electric car company. Earnings remained a key theme in intraday trading as well. ShockWave Medical (NASDAQ:SWAV), BioNTech (NASDAQ:BNTX) and Scientific Games (N...

The following slide deck was published by bluebird bio, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: bluebird bio, Inc. 2021 Q2 - Results - Earnings Call Presentation

Gainers: SCWorx (NASDAQ:WORX) +32%, Liminal BioSciences (NASDAQ:LMNL) +28%, Allied Healthcare Products (NASDAQ:AHPI) +20%, Windtree Therapeutics (NASDAQ:WINT) +17%, NRx Pharmaceuticals (NASDAQ:NRXP) +15%. Losers: Axsome Therapeutics (NASDAQ:AXSM) -42%,&...

- On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway following separation – - Severe genetic disease (SGD) business to scale back operations in Europe to focus on the U.S. market - - ABECMA ...

AMRX,APD,AVYA,BALY,BHVN,BLUE,BNTX,CEVA,CRNC,DISH,EBIX,ELAN,ENR,EPZM,GOLD,GTES,KOD,RDNT,SGMS,SWAV,SYNH,TGNA,TSN,TTD,USFD,VTRS,VTR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

bluebird bio, Inc. (NASDAQ: BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET. Investors may listen t...

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 85,000 shares of common stock and 50,000 restricted stock units (“RSUs”) to a new...

Despite recently getting its third drug approved, Bluebird Bio (NASDAQ: BLUE) only has a $1.7 billion market cap . Will the company overcome its past pricing issues and fly to new highs? And could its lead in sickle cell disease clinical trials translate into massive gains for i...

National Resilience and bluebird bio (BLUE) announce a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.BLUE shares up 2% premarket at $26.44.As part of the agreement, Resilience will acquire bluebird’s Research Triangle (b...